Clinical Trial Update: A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC [Phase 1]

View source ↗

Summary

Open-label Phase 1 cohort study evaluating curcumin in combination with tyrosine kinase inhibitors for patients with EGFR-mutant advanced non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Curcumin (curcumin)
• Tyrosine kinase inhibitors (TKIs) (tyrosine kinase inhibitors)

Snippet

Sponsor: Lady Davis Institute | Conditions: Lung Cancer | Phase 1 | Status: UNKNOWN